Cargando…

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives

OBJECTIVE: Patient preferences can be informative for health technology assessment (HTA) and payer decision making. However, applications may be different per country. The aim of this study therefore was to investigate HTA representatives’ opinions on whether and how to incorporate patient preferenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Overbeeke, Eline, Forrester, Valérie, Simoens, Steven, Huys, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794204/ https://www.ncbi.nlm.nih.gov/pubmed/32856278 http://dx.doi.org/10.1007/s40271-020-00449-0

Ejemplares similares

Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia
por: van Overbeeke, Eline, et al.
Publicado: (2021)

Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice
por: Janssens, Rosanne, et al.
Publicado: (2018)

Patient Centricity in Patient Preference Studies: The Patient Perspective
por: van Overbeeke, Eline, et al.
Publicado: (2020)

A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies
por: Hoxhaj, Ilda, et al.
Publicado: (2020)

Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey
por: van Overbeeke, Eline, et al.
Publicado: (2021)

Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study
por: van Overbeeke, Eline, et al.
Publicado: (2020)

Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study
por: De Weerdt, Elfi, et al.
Publicado: (2017)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)

Financial based agreements and performance based agreements: the Belgian experience
por: Pauwels, Kim, et al.
Publicado: (2015)

What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population
por: Pauwels, Kim, et al.
Publicado: (2019)

Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study
por: Abdallah, Khadidja, et al.
Publicado: (2022)

Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
por: Barbier, Liese, et al.
Publicado: (2021)

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective
por: Kisser, Agnes, et al.
Publicado: (2021)

Assessment of Methodological Quality of Economic Evaluations in Belgian Drug Reimbursement Applications
por: Simoens, Steven
Publicado: (2013)

Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review
por: Janssens, Rosanne, et al.
Publicado: (2019)

Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study
por: Wahlster, Philip, et al.
Publicado: (2015)

HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19
por: Warttig, S, et al.
Publicado: (2022)

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
por: Pauwels, Kim, et al.
Publicado: (2016)

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
por: Makady, Amr, et al.
Publicado: (2017)

R&D Costs of New Medicines: A Landscape Analysis
por: Simoens, Steven, et al.
Publicado: (2021)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study
por: van Overbeeke, Eline, et al.
Publicado: (2019)

Health technology assessment (HTA) increasingly important in spine research
por: van Tulder, Maurits
Publicado: (2011)

Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium
por: Vandeborne, Liese, et al.
Publicado: (2019)

Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US
por: Whichello, Chiara, et al.
Publicado: (2019)

Hospital-based health technology assessment (HTA) in Finland: a case study on collaboration between hospitals and the national HTA unit
por: Halmesmäki, Esa, et al.
Publicado: (2016)

Off-label use of orphan medicinal products: a Belgian qualitative study
por: Dooms, Marc, et al.
Publicado: (2016)

Health technology assessment (HTA) and economic evaluation: efficiency or fairness first
por: Richardson, Jeff, et al.
Publicado: (2018)

Landscape analysis of health technology assessment (HTA): systems and practices in Asia
por: Teerawattananon, Yot, et al.
Publicado: (2019)

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
por: Blonda, Alessandra, et al.
Publicado: (2021)

Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
por: Abdallah, Khadidja, et al.
Publicado: (2021)

Patient Preferences in Rare Diseases: A Qualitative Study in Neuromuscular Disorders to Inform a Quantitative Preference Study
por: Jimenez-Moreno, A. Cecilia, et al.
Publicado: (2021)

Practical Implications From European Hospital Pharmacists on Prospective Risk Assessment for Medicine Shortages
por: Miljković, Nenad, et al.
Publicado: (2020)

Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA
por: Janssens, Rosanne, et al.
Publicado: (2019)

Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland
por: Lebioda, Andrea, et al.
Publicado: (2014)

Correction to: Patient Preferences in Rare Diseases: A Qualitative Study in Neuromuscular Disorders to Inform a Quantitative Preference Study
por: Jimenez-Moreno, A. Cecilia, et al.
Publicado: (2021)

Patient advocate perspectives on involvement in HTA: an international snapshot
por: Scott, Anna Mae, et al.
Publicado: (2017)

How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice
por: Tafuri, Giovanni, et al.
Publicado: (2016)

Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
por: Culyer, Anthony J.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2if3hfdua9ja27nqhridv2tfkf